|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 2620450 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13155091.5 |
| Date of filing the European patent application | 2006-03-02 | |
| (97) | Date of publication of the European application | 2013-07-31 |
| (45) | Date of publication and mention of the grant of the patent | 2018-11-07 |
| (46) | Date of publication of the claims translation | 2019-02-11 |
| (30) | Number | Date | Country code |
| 659766 P | 2005-03-08 | US | |
| 728165 P | 2005-10-19 | US | |
| 752712 P | 2005-12-20 | US | |
| 762456 P | 2006-01-26 | US |
| (72) |
Abate, Justin Donald, US
Das, Tapan Kanti, US
Elliott, Carrie Marie, US
Muthurania, Kevin Wamiti, US
Nema, Sandeep, US
Singh, Satish Kumar, US
|
| (73) |
Pfizer Products Inc.,
Eastern Point Road, Groton, CT 06340,
US
|
| (74) |
Tatjana STERLINA,
UAB "Intels", Naugarduko g. 32/2, LT-03225 Vilnius,
LT
|
| (54) | Anti-CTLA-4 antikūnų kompozicijos |
| ANTI-CTLA-4 ANTIBODY COMPOSITIONS |
| Payment date | Validity (years) | Amount | |
| 2025-02-18 | 20 | 347.00 EUR |